- Home
- SAVA vs JHI Comparison
SAVA vs JHI Comparison
Compare SAVA & JHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- JHI
- Stock Information
- Founded
- SAVA 1998
- JHI 1971
- Country
- SAVA United States
- JHI United States
- Employees
- SAVA N/A
- JHI N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- JHI Trusts Except Educational Religious and Charitable
- Sector
- SAVA Health Care
- JHI Finance
- Exchange
- SAVA Nasdaq
- JHI Nasdaq
- Market Cap
- SAVA 135.9M
- JHI 124.3M
- IPO Year
- SAVA N/A
- JHI N/A
- Fundamental
- Price
- SAVA $2.75
- JHI $14.01
- Analyst Decision
- SAVA Buy
- JHI
- Analyst Count
- SAVA 3
- JHI 0
- Target Price
- SAVA $111.50
- JHI N/A
- AVG Volume (30 Days)
- SAVA 3.4M
- JHI 29.5K
- Earning Date
- SAVA 02-26-2025
- JHI 01-01-0001
- Dividend Yield
- SAVA N/A
- JHI 6.80%
- EPS Growth
- SAVA N/A
- JHI N/A
- EPS
- SAVA N/A
- JHI 1.05
- Revenue
- SAVA N/A
- JHI N/A
- Revenue This Year
- SAVA N/A
- JHI N/A
- Revenue Next Year
- SAVA N/A
- JHI N/A
- P/E Ratio
- SAVA N/A
- JHI $12.47
- Revenue Growth
- SAVA N/A
- JHI N/A
- 52 Week Low
- SAVA $2.23
- JHI $11.63
- 52 Week High
- SAVA $42.20
- JHI $13.40
- Technical
- Relative Strength Index (RSI)
- SAVA 30.54
- JHI 53.34
- Support Level
- SAVA $2.65
- JHI $13.84
- Resistance Level
- SAVA $2.83
- JHI $14.17
- Average True Range (ATR)
- SAVA 0.24
- JHI 0.11
- MACD
- SAVA 0.59
- JHI 0.03
- Stochastic Oscillator
- SAVA 52.75
- JHI 69.31
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
About JHI John Hancock Investors Trust
John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others.